We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nuformix Plc | NFX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.185 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.185 | 0.185 |
| Industry Sector |
|---|
| NONEQUITY INVESTMENT INSTRUMENTS |
| Top Posts |
|---|
Posted at 01/3/2024 20:29 by institutional investments I'd not be surprised to see a decent rally on no news with this complete . It's not in the back of investor minds anymore |
Posted at 09/2/2024 00:22 by jotoha2 Problem here is that Dan is not very good at painting a good picture of the so called link with a major partner , small investors have kept this company alive , so lets have some returns please Mr Dan . |
Posted at 04/1/2024 10:18 by jotoha2 Dan is talking to possible partners / investors , question is are they likely to lead to substantial results for the business . |
Posted at 09/9/2023 15:38 by for fx sake I was talking about real volume from real investors, not the blips afforded by P&D merchants. |
Posted at 05/7/2023 09:02 by oapknob1 The Subscription has been undertaken with a single UK-based FCA regulated institutional investor.Have they finished flipping the first 35,000,000 yet ?Would fund the warrants nicely. If the Warrants were ultimately to be exercised in full, it would result in the issue of an additional 35,000,000 new ordinary shares raising a further GBP87,500 |
Posted at 27/3/2023 07:29 by manual dexterity Nuformix PLC NXP002 Update27/03/2023 7:00am UK Regulatory (RNS & others) Nuformix (LSE:NFX) Intraday Stock Chart Monday 27 March 2023 Click Here for more Nuformix Charts. TIDMNFX RNS Number : 2322U Nuformix PLC 27 March 2023 27 March 2023 Nuformix plc ("Nuformix" or the "Company" or the "Group") NXP002 Update Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following update regarding the Company's NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). The Company recently announced the commencement of studies using a new iteration of a 3D human IPF lung tissue model - a high-challenge, disease and species relevant pre-clinical model with its partner, Fibrofind. Advancements within this model were designed to significantly reduce output variability. The Company has now received results from these studies of NXP002 alone and in combination with current standards of care ("SoC"), and they can be summarised as follows: -- NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events; -- NXP002 alone delivers a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis; -- Both high and low concentrations of NXP002 show an additive anti-fibrotic effect to SoC; -- In particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis biomarker release, yet at lower concentrations than have been seen in other pre-clinical models to date; and -- The clear, pronounced additive benefit of NXP002 on top of SoCs observed suggests that NXP002 will provide additional efficacy, even in patients responding to SoC therapy. This raises the possibility that NXP002 targets additional disease pathways to SoC's when increasing the combined anti-fibrotic response. Overall, the results provide further support of NXP002's potential to increase efficacy of existing therapies with the benefits of inhaled delivery (e.g. added efficacy without increased side effects). They also support NXP002's potential as a monotherapy for patients declining SoCs - a meaningful proportion of IPF patients who choose against the side effects of SoCs, which impact quality of life. Following the success achieved in these studies the Company's next steps include: -- Investigation of inflammation-related biomarkers in the same tissue sample sets to confirm additional mechanistic and anti-inflammatory benefits on top of SoC's, given the positive anti-fibrotic response; -- Expansion of the current study to include tissue from an additional two further human IPF tissue donors to demonstrate the robustness of NXP002's anti-fibrotic response alone and in SoC combinations in multiple patients; and -- To consider the expansion of the Company's on-going healthy lung tissue study investigating NXP002's duration of action to three donors, based on results when received. Understanding the performance of new IPF therapies with SoC's has become critical to both potential development partners and regulators. Therefore, the Company believes completion of these steps is required for Nuformix to secure the interest of out-licensing partners. Results will continue to be generated with further updates announced when appropriate . Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: " All parties are delighted with the results from this study, which are as good as we could have hoped for and are the first results from what is the most advanced iteration of this 'close to patient' IPF disease model to date. The reduced variability in the resulting data allows us to have high confidence in both NXP002's anti-fibrotic activity alone, but also in the added anti-fibrotic performance it can deliver on top of existing standards of care. Additivity to standard of care is the most important aspect because it's the simplest option to investigate in a clinical study and is therefore fast becoming a top priority for potential licensing partners. Having seen the quality of these results, our aim now is to generate datasets from three donors in both human IPF and healthy lung duration of action studies. These data can be generated quickly and will be essential in opening up new discussions with potential licensing partners and support overall progression of the NXP002 programme." Enquiries: Nuformix plc Dr Dan Gooding, Executive Director Via IFC Advisory Stanford Capital Partners Limited Tom Price / Patrick Claridge (Corporate Finance) +44 (0) 20 3650 3650 John Howes (Corporate Broking) +44 (0) 20 3650 3652 IFC Advisory Limited Tim Metcalfe +44 (0) 20 3934 6630 Zach Cohen nuformix@investor-fo |
Posted at 20/6/2022 14:12 by pwhite73 The same process has started again, afternoon selling. Lanstead are leaving this company other investors should consider doing likewise. |
Posted at 17/6/2022 16:52 by amaretto1 And listen you tool CPI fund have been selling for years It's a none profitable investor Clown |
Posted at 10/6/2022 08:09 by for fx sake What about our listing status and how are going to attract new investors if we are a plc and have no executive directors?What if Julian Gilbert throws in the towel?We are in a very precarious position. If one of the previous directors (JH or DG) was to step and fill the CEO then, at least, it would show that there some confidence here. They have the most relevant experience and knowledge.Question is, why won't they? |
Posted at 21/10/2021 11:32 by inipvestor Nuformix PLC (LON: NFX) share price surged 12.7% despite the pharmaceutical company not making significant announcements today. Here's why.The lack of news from the company indicates that today's move higher was primarily driven by buying pressure from investors and positive sentiment. The last significant announcement from Nuformix was in September when it signed an exclusive licensing deal with Oxilio Ltd to develop and commercialise its cancer drug.While there is no direct trigger behind today's rally, we know that the one single driver behind a rallying share price is buying pressure.Therefore, we can confidently say that a wave of buying pressure has hit Nuformix share, triggering the rally.The buying pressure could be from a single institutional investor accumulating a significant position in the pharma company, or it could be from a group of investors with a bullish view of the stock.From a technical analysis standpoint, Nuformix shares have pushed back above the crucial 1.30p resistance level that could now act as support.However, we would need to see further gains before saying that the resistance level has turned into support. Currently, we could see the price fail to hold above the level leading to a further decline.Investors interested in opening new bullish positions in the stock should wait for the price to hold above the support zone and retest it before jumping in.People Who Read This Also ReadSensyne Health Share Price Trades Sideways Despite EU Regulatory ApprovalCeres Power Share Price Edged Higher After Appointing a New CFOPhoenix Copper Share Price Climbs As ADR's to Begin US Tr |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
